Amneal Recalls Exenatide Injection Pens Due to Potential Empty Delivery System
Amneal Pharmaceuticals is recalling 5,694 Exenatide Injection pens because the delivery system may be defective, potentially leaving the pen empty of medication.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 3/5 (High).
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: The recall is classified as FDA Class II, and the hazard involves a risk of harm (lack of medication) where injury has not yet been reported, fitting the 'High' severity criteria for risk-of-harm products.
Plain-English summary
Amneal Pharmaceuticals of New York, LLC is recalling 5,694 pens of Exenatide Injection, USP, 250 mcg/mL, 1.2 mL per prefilled pen. The recall is due to a defective delivery system that may result in no medication being present in the prefilled pen. The affected product is identified by Lot # AP250095A with an expiration date of 2/28/2027 and NDC 70121-1685-1.
The product was distributed nationwide in the United States. Exenatide is a prescription-only medication intended for subcutaneous use for single patient use only. It is manufactured by Amneal Pharmaceuticals Pvt. Ltd. in India and distributed by Amneal Pharmaceuticals LLC in Bridgewater, NJ.
Patients and healthcare providers should check their inventory for the specific lot number and expiration date listed above. If the product matches the recalled lot, it should not be used. Consumers should contact their healthcare provider or pharmacist for guidance on alternative treatment options or replacement medication.
The recalled product
- Product
- EXENATIDE (EXENATIDE)
- Brand
- EXENATIDE
- Manufacturer
- Amneal Pharmaceuticals of New York, LLC
- Category
- Drug — Prescription Injection
- Affected units
- 5,694
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: AP250095A
- Exp 2/28/2027
Distribution
Distributed nationwide across the United States.
Related recalls
Same manufacturer · Amneal Pharmaceuticals of New York, LLC
See all →- HighMethylergonovine Maleate tablets recalled for failed dissolution specifications
FDA (Drugs) · 2024-05-08
- SevereVancomycin Hydrochloride Oral Solution Recalled Nationwide for Superpotency Due to Overfilling
FDA (Drugs) · 2024-04-24
- HighDivalproex Sodium 250 mg tablets recalled for failed dissolution specifications
FDA (Drugs) · 2024-04-03
- ModerateFDA Recalls Oseltamivir Phosphate Oral Suspension for Out-of-Specification Impurities
FDA (Drugs) · 2024-02-28
- HighAmneal Phenoxybenzamine Hydrochloride Capsules 10mg Recalled Due to Unknown Impurity
FDA (Drugs) · 2024-02-14
Same hazard · defective delivery system
See all →- ModerateCetrorelix injection kits recalled over missing or duplicated needles inside
FDA (Drugs) · 2026-02-18
- HighAIRSUPRA Albuterol and Budesonide Inhalation Aerosol Recalled for Defective Delivery System
FDA (Drugs) · 2025-05-28
- HighLorazepam Oral Syringes Recalled Due to Defective Delivery System Causing Leakage
FDA (Drugs) · 2025-03-12
- ModerateVarithena Administration Pack Recalled Due to Incorrect Syringe Connector Type
FDA (Drugs) · 2024-12-18
- HighDaytrana Methylphenidate Transdermal Patches Recalled for Defective Delivery System
FDA (Drugs) · 2023-03-29
Similar recalls
- SevereAmneal Recalls Fosphenytoin Sodium Injection Due to Particulate Matter
FDA (Drugs) · 2017-11-22
- ModerateAmneal Recalls Extended Phenytoin Sodium Capsules Due to Dissolution Failure
FDA (Drugs) · 2013-11-13
- LowExela Pharma Recalls Potassium Acetate Injection Vials Due to Short Fill
FDA (Drugs) · 2020-09-23
- SevereAmneal Recalls Lorazepam Oral Concentrate Due to Defective Dropper Markings
FDA (Drugs) · 2017-12-27
- SevereAmneal Recalls Ranitidine Tablets Due to NDMA Impurity
FDA (Drugs) · 2019-12-18
- HighAmneal Phenoxybenzamine Hydrochloride Capsules 10mg Recalled Due to Unknown Impurity
FDA (Drugs) · 2024-02-14